Purpose The blood-brain barrier discriminates the access of several molecules to the brain. This hampers the use of some drugs, as doxorubicin, potentially active for treatment of brain tumors. We explored the feasibility of active modiWcation of the blood-brain barrier protection, by using morphine pretreatment, to allow doxorubicin accumulation in the brain in an animal model. Methods Rats were pretreated with diVerent doses of intraperitoneal morphine before injection of doxorubicin (12 mg/kg). Quantitative analysis of doxorubicin was performed by mass spectrometry. Acute heart and kidney damage was analyzed by measuring doxorubicin accumulation, LDH activity and malondialdehyde plasma levels. Results The concentration of doxorubicin was signiWcantly higher in all brain areas of rats pretreated with morphine than in control tissues (P < 0.001). This was evident only at therapeutic morphine dose (10 mg/kg, three times over 24 h), while lower doses (2.5 and 5 mg/kg) were not associated with doxorubicin accumulation. Pretreatment with morphine did not induce an elevation of LDH activity or of lipid peroxidation compared to controls. Conclusion Our data suggest that morphine pretreatment is able to allow doxorubicin penetration inside the brain, by modulating the blood-brain barrier. This is not associated with acute cardiac or renal toxicity. These preliminary results will enable us to generate novel therapeutic approaches to refractory or recurrent brain tumors, and might be useful in other human diseases of the central nervous system in which molecules usually stopped by the blood-brain barrier may have a therapeutic impact.
Introduction
Despite recent advances in the cure of childhood cancer, brain tumor still lags behind other cancer types [1, 2] . Although the reason for treatment failure may depend on several issues, inadequate eYcacy of chemotherapy probably plays a major role, compared to what has been achieved in other cancer types.
Based on in vivo and in vitro studies, brain tumors might be expected to be sensitive to chemotherapy agents, as anthracyclines [3, 4] . Yet, most patients fail to achieve adequate disease control due to insuYcient cytoreduction of unresectable tumors, or develop tumor relapse despite apparent gross-total resection and/or irradiation [2] .
One major obstacle to eYcient tumor cytoreduction may be insuYcient drug delivery to the tumor site. The bloodbrain barrier (BBB) is a physical and metabolic barrier between systemic circulation and the brain. It maintains homeostasis and protects the brain from toxic insults. Yet, BBB may represent a real limiting factor to delivering chemotherapy agents within the brain tumor mass.
Morphine is the most used narcotic analgesic. In a recent report, Sharma and coworkers using a rodent model documented that morphine induced a transient alteration of BBB permeability to large molecules [5] . We hypothesized that a reversible modulation of the BBB by morphine might act as permeability enhancer for chemotherapy agents and designed an experimental rat model with the aim to achieve permeability of the BBB to doxorubicin by morphine pretreatment. Here, we demonstrate that doxorubicin concentration in the brain is greatly enhanced when doxorubicin is administered in the presence of therapeutic plasma levels of morphine.
Methods

Drugs and reagents
Doxorubicin (Adriblastina, Farmitalia Carlo Erba, Milan, Italy) 12 mg/kg in sterile H 2 O was administered i.p. in a volume of 6 ml/kg [6] . Morphine (10 mg/kg) was dissolved in sterile saline and administered i.p. in a volume of 4 ml/kg.
Chemical standard of Doxorubicin hydrochloride (purity > 98%) was purchased from Sigma-Aldrich (Steinheim, Germany); the internal standard, Doxorubicin-13 C 4 (99.8% D purity) was from Medical Isotopes Inc. (Pelham, USA). Stock solutions of both were made in HPLC grade methanol (2,000 mg/l). Further dilutions were made using HPLC grade water. All chemicals and solvents were of the highest purity available from commercial sources and used without further puriWcation.
Animals
Male adult Wistar rats (260-280 g) were used (Harlan Italia, Milano, Italy). All animal manipulations were carried out according to the European Community guidelines for animal care (DL 116/92, application of the European Communities Council Directive 86/609/EEC). All eVorts were made to minimize animal suVerings and to use only the number of animals necessary to produce reliable scientiWc data. Rats were randomly allocated to one of the following experimental groups (5 animals per group):
Group 1 (D + M): on day 1, rats were treated twice with morphine (10 mg/kg, i.p., at 10.00 a.m. and again at 5.00 p.m.); on day 2 at 10.00 a.m., they received a third dose of morphine; 1 h later they received i.p. doxorubicin. Group 2 (D): rats were treated with doxorubicin alone. Group 3 (Ctr): naïve rats received no drugs.
Neurological test
Neurological evaluation of motor sensory functions was carried out 10 days after doxorubicin administration on two groups of rats: (a) rats treated as group 1 animals (n = 4) and saline-treated rats (n = 4) as controls. The examiners were blind as to the procedure that the rat had undergone. Evaluations were performed in the afternoon. The neurological examination consisted of six tests: (1) spontaneous activity; (2) symmetry in the movement of four limbs; (3) forepaw outstretching; (4) climbing; (5) body proprioception; (6) response to vibrissae touch. The score assigned to each rat at completion of the evaluation equals the sum of all six test scores. The Wnal minimum score was 3 and the maximum was 18 [7, 8] . Rats were weighted every day.
Collection of tissues
One hour after administration of doxorubicin, rats were deeply anesthetized with chloral hydrate (400 mg/kg, i.p.). The heart was exposed and blood was withdrawn by intracardiac puncture, collected in a preheparinized plastic tube, plasma was separated from blood cells. Animals were then perfused transcardially with ice-cold saline (500 ml, 50 ml/ min). At the end of perfusion, the cerebral hemispheres, the cerebellum, and brainstem were dissected; heart and kidney were collected; all tissues were rinsed in ice-cold saline and transferred to screw-capped plastic tubes. All tissues were immediately frozen on dry ice and kept at ¡80°C until assay.
Quantitative analysis of doxorubicin by mass spectrometry
Doxorubicin determination on plasma
To quantify plasma concentration of doxorubicin, samples (25 L) were spotted on Wlter paper (903 ® , Whatman GmbH, Dassel Germany) and air-dried. Dried plasma spots were punched and two 3. For the setting up of this study, a pooled mixture of plasma samples from untreated rats was spiked with increasing concentrations of doxorubicin and 25 L was spotted on 903 ® Wlter paper.
Tissue sample preparation
Thawed brain sections (cerebral hemispheres, brainstem, and whole brain) were weighed and spiked with 2 L of 13 C 4 -doxorubicin (10 mol/l) directly injected into the tissue. After 10 min, the sections were diluted with 2.5 ml H 2 O. Sample homogenization was performed using a mechanical homogenizer (UltraTurrex, IKA-Werke, Staufen, Germany) followed by 10 min of intermittent ultrasonication in the ice bath. Samples were defatted using 2 ml of chloroform with vigorous shaking for 5 min, followed by centrifugation at 3,000 rpm for 10 min. The aqueous upper phase was transferred to a new tube, and the chloroform extraction step was repeated 6 times. After the last extraction acetonitrile (400 L) was added and precipitates removed by centrifugation at 13,200 rpm for 3 min, the samples were dried out and rehydrated with acidiWed methanol (0.1% formic acid, v/v) 300 L. To determine the extraction yield of doxorubicin, brain tissue samples from an untreated rat were spiked with doxorubicin (5 mol/l) before and after extraction process.
Mass spectrometry
An Applied Biosystems-Sciex (Toronto, Canada) API 4000 bench-top TurboIonSpray-Triple-Quad Mass Spectrometer (MS/MS) was used for this study. The ion source operated under positive ion mode (5,500 V). Declustering potential (DP), collision exit potential (CXP) and collision energy (CE) were automatically optimized for doxorubicin and 13 C 4 -doxorubicin. The resulting DP was 35 V. Optimal CE and CXP were found at 16 and 10 V, respectively ( Fig. 1) .
Quantitative analysis was undertaken using an HPLC Series 1100 Agilent Technologies (Waldbronn, Germany). Liquid chromatography was performed using a Phenomenex Synergi 4 m Polar-RP 80A 4 m, 2 £ 150 mm HPLC column (Phenomenex, Anzola Emilia, Italy) injecting 5 L of the extracted sample. Column Xow was 0.2 ml/min using an isocratic aqueous solution of 80% methanol containing 0.1% formic acid. The eluent from the column was directed to the TurboIonSpray probe without split ratio.
LDH activity and tissue lipid peroxidation
Lactate dehydrogenase (LDH) activity was measured in rat plasma using the Cytotoxicity Detection Kit (Roche Diagnostics GmbH, Mannheim, Germany) and absorbance read at 490 nm.
Tissue lipid peroxidation in terms of malondialdehyde (MDA) production (thiobarbituric acid-reactive species) was determined as previously described [9] .
Statistical analysis
Statistical signiWcance was evaluated using one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison test as a post hoc analysis or by Student's t test, as appropriate. A P value of 0.05 or less was taken as the criterion for statistically signiWcant diVerence.
Results
The concentration of doxorubicin within the brain tissue was signiWcantly higher in rats pretreated with morphine than in those treated with doxorubicin alone. Doxorubicin was undetectable in control samples from untreated rats (Fig. 2) .
Doxorubicin concentration was signiWcantly higher in all the brain areas under study of animals pretreated with morphine ( Fig. 3) .
Cerebral hemispheres: the mean concentration of doxorubicin in the cerebral hemispheres of rats receiving doxorubicin alone was 5.88 § 0.34 ng/g fresh tissue (n = 5) versus 18.8 § 1.01 ng/g fresh tissue in those treated with doxorubicin plus morphine (n = 5), while control animals had no doxorubicin (0.002 § 0.001 ng/g fresh tissue, n = 3). The estimated limit of detection of doxorubicin (signal-to-noise ratio > 3) in the brain was 1 ng/g fresh tissue, and the limit of quantitation (signal-to-noise ratio > 5) was 2 ng/g fresh tissue. This diVerence was statistically signiWcant (one-way ANOVA F[2, 10] = 168.3, P < 0.0001; *** P < 0.001 versus all other groups, Newman-Keuls post hoc test).
Cerebellum: the mean concentration of doxorubicin in the cerebellum of rats receiving doxorubicin alone was 5.18 § 0.38 ng/g fresh tissue (n = 5) versus 15.94 § 0.371 ng/g fresh tissue in those treated with doxorubicin plus morphine (n = 5), while control animals had no doxorubicin (n = 3). This diVerence was statistically signiWcant (one-way ANOVA F[2, 10] = 482.0, P < 0.0001; *** P < 0.001 versus all other groups, Newman-Keuls post hoc test).
Brainstem: the mean concentration of doxorubicin in the brainstem of rats treated with doxorubicin alone was 5.71 § 0.38 ng/g fresh tissue (n = 5) versus 14.6 § 0.25 ng/g fresh tissue in those treated with doxorubicin plus morphine (n = 5). Control animals had no detectable doxorubicin (0.001 § 0.001 ng/g fresh tissue, n = 5). This diVerence was statistically signiWcant (one-way ANOVA F[2, 10] = 521.2, P < 0.0001; *** P < 0.001 versus all other groups, Newman-Keuls post hoc test).
Pretreatment of rats with lower doses of morphine (5 or 2.5 mg/kg, three times in 24 h, i.p.) failed to facilitate doxorubicin entry into the brain (n = 3; data not shown).
Mean plasma levels of doxorubicin in animals pretreated with morphine (12.89 § 0.71 mol/l plasma, n = 5) did not diVer from that found in rats receiving doxorubicin alone (13.26 § 2.12 mol/l plasma, n = 5) (P = 0.8711, Student's t test) (Fig. 4a) .
Cardiac and renal toxicity after treatment with an anthracycline is a matter of great concern. We therefore investigated whether pretreatment with morphine might increase the doxorubicin concentrations in the heart and kidney, thus predicting increased toxicity in these two target organs. Pretreatment with morphine did not increase the levels of doxorubicin in either tissue at 1 h after administration (P > 0.05, Student's t test, Fig. 4b, c) .
We addressed the issue of cardiac and renal toxicity by analysis of plasma LDH activity and MDA levels. Doxorubicin induced a 60% increase in plasma LDH activity 1 h after treatment in treated versus control rats (Table 1 , P = n.s.). No diVerence in LDH activity was found between rats treated with doxorubicin alone and those receiving morphine plus doxorubicin.
Mean MDA plasma levels were not statistically diVerent among the three groups (Table 1) .
In order to clarify whether the concomitant administration of doxorubicin and morphine might cause any late neurological toxicities/mortalities, we followed a group of rats for 10 days after the administration of the two drugs. We did not observe any clear sign of clinical toxicity nor any of the animals died after treatment. Rats treated with doxorubicin plus morphine did not show any neurological deWcit 17.75 § 0.25). Rats treated with morphine plus doxorubicin had signiWcant body weight loss for the Wrst 6 days after treatment, after which they started to gain weight.
Discussion
The main result of our study is that pretreatment with morphine at therapeutic dose allows delivery of doxorubicin within the brain tissue, which is otherwise precluded by the blood-brain barrier. Penetration of doxorubicin appears to be unrestricted to the diVerent areas of the brain.
A prerequisite for the eYcacy of a cytotoxic drug for the treatment of cancer is its capacity to reach the tumor cell at therapeutic concentrations. For brain tumors, this goal is usually hampered by BBB, a structure with the delicate duty to preserve, as far as possible, the integrity of brain tissue from chemical or infectious hazards.
Recently, Sharma et al. reported that rats treated with morphine exhibited leakage of albumin in several brain areas. This phenomenon was much more pronounced on the second and third day after morphine withdrawal, and was associated with ultrastructural changes in the nerve and glial cells [5] . The authors hypothesized that neurochemical mediators and vasoactive agents act on the vessels through signal transduction pathways leading to the opening of the BBB. Based on these data, we decided to investigate the possibility of morphine-mediated active BBB permeabilization.
Morphine is a substrate of the MDR1 isoform of P-glycoprotein (P-gp) eZux transporter, which very eYciently removes several molecules and drugs from the CNS, thus limiting their entry into the brain. Morphine-mediated "accumulation" of doxorubicin in the brain might result from its reduced eZux mediated by P-gp at the level of the BBB cells [10] . P-gp is localized mostly at the apical side of brain endothelial cell membrane. P-gp substrates Xowing into the endothelial cells are rapidly pumped back into the blood, thus preventing them from entering the brain. This hypothesis is supported by evidence that P-gp blockade by speciWc inhibitors results in a signiWcantly increased brain concentration of some antiepileptic drugs [10] . Whether alternative or additional mechanisms may mediate the impact of morphine and other opioid drugs on the BBB remains to be elucidated further [11] [12] [13] .
Data on the eVects of chronic exposure to morphine are conXicting [14, 15] . In rats chronically treated with morphine, in situ perfusion of sucrose did not allow its penetration into the BBB [15] . These data might be considered at odds with our results. Yet, we documented that an antiblastic drug-doxorubicin-accumulated in the brain and was detected by mass spectrometry, a highly precise, reliable, and sensitive method. Furthermore, several studies demonstrate that morphine and doxorubicin use the same eZux channels [10, 16] , whereas sucrose crosses BBB by diVusion. We consider these data not to be an argument against our results.
On the other side, our group has recently reported unexpected respiratory distress as enhanced toxicity of dimethylsulfoxide (DMSO) on the central nervous system of children receiving morphine during hematopoietic stem cell transplantation. While this Wnding was apparently unexplained, we now consider that DMSO may have had undesired access to the brain tissue due to concurrent morphine-mediated temporary alteration of the BBB [17] .
Delivering speciWc drugs beyond the BBB may open novel therapeutic approaches for several human diseases [18] . Pioneer experience in the treatment of childhood leukemia brought to intrathecal injection [19] . Yet, intrathecal chemotherapy can be adopted with great caution and only for a very limited number of drugs. Inadvertent intrathecal administration of anthracycline turned into catastrophic toxicity [20, 21] . Intracarotid infusion of hyperosmolar mannitol has been used to disrupt the BBB with the aim to increase the delivery of water-soluble agents into the brain and peritumoral areas [22] . Although this method gave some promising results, it requires an invasive surgical approach, with high risk of adverse eVects that limit its potential clinical application on a large scale. More recently, nanoparticles have been adopted to enhance the transport of therapeutic agents across the BBB, providing reWned drug delivery [23] .
Doxorubicin accumulation was achieved after pretreatment with therapeutic dose of morphine. When we tried to document this phenomenon with lower doses of morphine pretreatment (25 and 50% dose), we did not document any accumulation compared to control rats, not pretreated with morphine. Thus, permissive eVect of morphine appears to be active only beyond a threshold dose. Moreover, our data demonstrate that the concentration of doxorubicin after morphine pretreatment was signiWcantly higher in cerebral hemispheres than in cerebellum and brainstem (Fig. 3) . This result may depend upon a diVerent structure of BBB or on a diVerent distribution of P-gp isoforms in these brain areas, making the brainstem less accessible to many molecules.
Although doxorubicin is a very eVective anti-cancer drug, its cardiac toxicity has to be considered as a potential limitation to unrestricted use. To evaluate whether doxorubicin toxicity might be enhanced by co-administration of morphine, thus leading to dangerous acute and/or chronic side eVects, we quantiWed doxorubicin levels in heart and kidney of morphine pretreated rats. Co-administration of morphine did not increase the levels of doxorubicin in either tissue 1 h after administration. We also evaluated plasma LDH activity and MDA levels, as markers of acute cardiotoxicity, and found no diVerence between rats treated with doxorubicin alone and those also receiving morphine (Fig. 4) . Table 1 Levels of LDH activity and MDA production in plasma of control rats, rats treated with doxorubicin alone or after pretreatment with morphine Doxorubicin was administered to diVerent groups of rats either alone (12 mg/kg, i.p., doxorubicin, n = 7) or after pretreatment with 3 doses of morphine (10 mg/kg each, i.p., three times in 24 h, Doxorubicin + Morphine, n = 6). Control animals (n = 6) received neither drug Values are the mean § SEM. Statistical signiWcance between means was analyzed using one-way ANOVA followed by the NewmanKeuls post hoc multiple comparison test. DiVerences In conclusion, our preliminary results indicate that morphine pretreatment mediates doxorubicin delivery beyond the BBB to the brain, in the absence of signs of increased acute toxicity. This Wnding might provide the rationale for clinical applications in the treatment of refractory brain tumors and pave the way to novel applications of active but currently inapplicable drugs. It remains to be assessed whether this observation will also facilitate studies exploring the brain delivery of other active agents, such as monoclonal antibodies or other macromolecules for the treatment of brain tumors or other human brain disease.
